A Randomized, Double-blind, Active Comparator Clinical Trial to Evaluate Safety and Immunogenicity of Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli) in People Ages 16 Years and Above
Latest Information Update: 28 Aug 2024
At a glance
- Drugs Hepatitis E vaccine recombinant (Primary)
- Indications Hepatitis E
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Xiamen Innovax Biotech
Most Recent Events
- 28 Aug 2024 New trial record